The Body PRO covers the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2009)


Featured Coverage

Wafaa El-Sadr, M.D., M.P.H. Inflammation and HIV: A New Paradigm
"During the long period when the person appears to be quite well, there are ongoing processes in their bodies, due to HIV itself ... that may be causing some damage, some unseen damage, that may ultimately have a very large impact on a person's survival, and a person's wellness," says Wafaa El-Sadr, M.D., M.P.H. El-Sadr, one of the world's most respected HIV researchers, made this key point at the IAS 2009 conference in the midst of an eloquent call for early HIV treatment and global access to HIV meds.
More Top Stories:

Developing WorldHIV Prevention
How Will Barack Obama Change the Global (and Domestic) Fight Against HIV?

Anthony Fauci, M.D. and Michel Kazatchkine, M.D., Ph.D.End the U.S. HIV travel ban? Check. Get federal funding for needle exchange? Check. Continue the U.S. commitment to paying for HIV treatment and care overseas? Check. In a wide-ranging discussion at IAS 2009, Anthony Fauci, M.D., Director of the U.S. National Institute of Allergy and Infectious Diseases, and Michel Kazatchkine, Executive Director of the Global Fund, outlined some of the Obama administration's plans to address HIV/AIDS domestically and abroad. (IAS 2009 coverage from The Body PRO)

Read or listen (39 min.):

More Highlights:

Revisiting Priorities in the Prevention of Mother-to-Child HIV Transmission

Louise Kuhn, M.P.H. In a talk focusing largely on the developing world, Louise Kuhn, M.P.H., drives home the importance of antiretroviral therapy for all pregnant or breastfeeding women with a CD4+ cell count below 350. She also urges a greater focus on long-term child health and survival, beyond simply preventing mother-to-child HIV transmission. (From The Body PRO)

More Highlights:

HIV/AIDS Treatment StrategiesComplications & Coinfections
African Americans, Women Have Lower Virologic Response Rates in Both Arms of Head-to-Head Antiretroviral Trial

Kimberly Smith, M.D., M.P.H.Race and gender may prove to be a more critical factor than we think in virologic response to HIV medications. In the large HEAT study, which compared two first-line HAART regimens, Kimberly Smith, M.D., M.P.H., et al found that in both study arms, fewer African Americans (versus white patients) and females (versus males) achieved a viral load of less than 50 copies/mL. (From The Body PRO)

Read or listen (4 min.):

More Highlights:

Two New Analyses Add to Abacavir Cardiovascular Risk Debate

Two studies presented at IAS 2009 found no association between abacavir and increased risk of heart attack or stroke, and underlined the importance of confounding risk factors. (From

More Highlights:

About This Conference

The Body PRO's coverage of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2009) will include a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.

For more information on IAS 2009, please visit the conference's Web site. You may also view the conference program online.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The Body PRO is an independent Web site not associated with this conference. The Body PRO provides medical education and information to health care professionals.

Latest Additions